Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Shalom, Guy; Naldi, Luigi; Lebwohl, Mark; Nikkels, Arjen F.; Jong, E.M.G.J. de; Fakharzadeh, Steven; Goyal, Kavitha; Bhaskar, Suryanarayanan; Langholff, Wayne; Galindo, Claudia; Cohen, Arnon D

doi:10.1080/09546634.2018.1445193

Cited by 20 publications

(22 citation statements)

References 22 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, three subjects in the ustekinumab group had herpes zoster infection versus none in the secukinumab group. These results are in line with previous studies that have suggested a higher rate of herpes zoster with ustekinumab treatment . Furthermore, the most common AE with secukinumab treatment included nasopharyngitis and upper respiratory tract infection.…”

Section: Discussionsupporting

confidence: 91%

“…These results are in line with previous studies that have suggested a higher rate of herpes zoster with ustekinumab treatment. 37,38 Furthermore, the most common AE with secukinumab treatment included nasopharyngitis and upper respiratory tract infection. Although, IL-17A is largely involved in downstream signaling of immune defense, targeting IL-17A may increase the risk of infection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study

Lee

Huang

Lee

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

The 52‐week results from the CLEAR (NCT02074982) study showed high and superior efficacy of secukinumab versus ustekinumab in clearing skin and improving patient‐reported outcomes, with comparable safety profile in subjects with moderate to severe psoriasis. Here, we analyzed the efficacy and safety of secukinumab in Asian subjects from the CLEAR study. In this double‐blind, phase IIIb study, eligible subjects with moderate to severe plaque psoriasis were randomized (1:1) to receive s.c. injection of secukinumab 300 mg or ustekinumab as per label. Of 62 subjects included in Asian subanalyses, 23 were randomized to secukinumab and 39 to ustekinumab. A significantly higher proportion of subjects achieved 90% or more improvement in Psoriasis Area and Severity Index (PASI 90) with secukinumab versus ustekinumab at week 16 (78.3% vs 35.9%, P = 0.0010) and at week 52 (60.9% vs 33.3%, P = 0.0196). Similarly, a higher proportion of subjects achieved PASI 100 with secukinumab versus ustekinumab at week 16 (43.5% vs 10.3%, P = 0.0029) and at week 52 (30.4% vs 12.8%, P = 0.0704). The median time to achieve 50% improvement in baseline PASI was 2.8 weeks in the secukinumab group versus 6.3 weeks in the ustekinumab group. The safety profile of secukinumab was in line with the known profile and no deaths occurred. Overall, 95.7% and 84.6% of subjects remained on secukinumab and ustekinumab, respectively. Similar to the core study, secukinumab showed sustained and superior efficacy with faster response versus ustekinumab, and no new or unexpected safety concerns were identified, in Asian subjects with moderate to severe plaque psoriasis.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study

Lee

Huang

Lee

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…In the Psoriasis Longitudinal Assessment and Registry (PSOLAR), rates of serious infection were lower for ustekinumab than for psoriasis patients not on a biologic (16,17). For herpes zoster, in particular, rates were slightly higher, but there were few cases, and differences were not statistically significant (18).…”

Section: Should Patients Stop Their Biologic Treatment During the Covmentioning

confidence: 99%

Should patients stop their biologic treatment during the COVID-19 pandemic

Bashyam

Feldman

2020

Journal of Dermatological Treatment

View full text Add to dashboard Cite

“…Patients in this study included elderly, children, pregnant and breastfeeding women and met the ethical requirements for enrollment in this study. With regard to the study design, we mainly focused on the Psoriasis Longitudinal Assessment and Registry [ 21 – 23 ] (PSOLAR) and the National Central Cancer Registry of China [ 24 ] (NCCR). The Psoriasis Registration Platform was designed to demonstrate, train researchers and to strictly adhere to standard operation process.…”

Section: Discussionmentioning

confidence: 99%

Traditional Chinese medicine for psoriasis vulgaris

et al. 2020

View full text Add to dashboard Cite

Introduction: The incidence of psoriasis vulgaris is increasing worldwide. Chronic recurrence of the disease, as well as accompanying cardiovascular disease, metabolic syndrome, and depression has affected the physical and mental health of these patients. Psoriasis vulgaris is a difficult and major disease in the dermatology field. Short-term curative effects using conventional therapy for psoriasis vulgaris has made major strides. However, traditional Chinese medicine (TCM) treatment has long-term curative advantages for psoriasis vulgaris but lacks the scientific and clinical evidence for its use. This study intends to demonstrate and provide scientific and clinical evidence for the use of TCM to delay the recurrence of psoriasis vulgaris. Methods and analysis: This will be a prospective, multicenter cohort study. We intend to recruit 1521 psoriasis vulgaris patients from 14 hospitals in Beijing, Tianjin, and Hebei. Treatment will be based on the diagnosis specifications and clinical practice guidelines of TCM and conventional therapy. During inclusion and the subsequent follow-up period, doctors through electronic case reports will collect different therapeutic TCM regimens and conventional therapy that were administered. Information on life condition, skin lesions at each visit, World Health Organization Quality of Life Instruments, Zung Self-rating Anxiety Scale, Zung Self-assessment of Depression, laboratory examinations, incidence of new rash and recurrence during the remission and recurrence stages will be recorded. Ethics and dissemination: The clinical trial protocol for this study was approved by the ethics committee of the Beijing hospital of TCM affiliated to capital medical university (Ethics number: 2019BL02-010-02). We will publish and present our results at national and international conferences and in peer-reviewed journals specialized in dermatology. Trial registration: This protocol has been registered in clinicaltrials. gov (ChiCTR1900021629)

show abstract

Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Cited by 20 publications

References 22 publications

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study

Should patients stop their biologic treatment during the COVID-19 pandemic

Traditional Chinese medicine for psoriasis vulgaris

Contact Info

Product

Resources

About